vs
Side-by-side financial comparison of Aflac (AFL) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.
Aflac is the larger business by last-quarter revenue ($4.3B vs $3.0B, roughly 1.5× Vertex Pharmaceuticals). Vertex Pharmaceuticals runs the higher net margin — 34.5% vs 23.4%, a 11.1% gap on every dollar of revenue. On growth, Aflac posted the faster year-over-year revenue change (27.9% vs 7.8%). Over the past eight quarters, Vertex Pharmaceuticals's revenue compounded faster (6.3% CAGR vs -8.0%).
Aflac Incorporated is an American insurance company and is the largest provider of supplemental insurance in the United States. It was founded in 1955 and is based in Columbus, Georgia. In the U.S., it underwrites a wide range of insurance policies, but is perhaps more known for its payroll deduction insurance coverage, which pays cash benefits when a policyholder has a covered accident or illness. The company states it "provides financial protection to more than 50 million people worldwide".
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
AFL vs VRTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.3B | $3.0B |
| Net Profit | $1.0B | $1.0B |
| Gross Margin | — | 86.8% |
| Operating Margin | — | 38.1% |
| Net Margin | 23.4% | 34.5% |
| Revenue YoY | 27.9% | 7.8% |
| Net Profit YoY | — | 59.6% |
| EPS (diluted) | $1.98 | $4.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $4.3B | $3.0B | ||
| Q4 25 | $4.9B | $3.2B | ||
| Q3 25 | $4.7B | $3.1B | ||
| Q2 25 | $4.2B | $3.0B | ||
| Q1 25 | $3.4B | $2.8B | ||
| Q4 24 | $5.4B | $2.9B | ||
| Q3 24 | $2.9B | $2.8B | ||
| Q2 24 | $5.1B | $2.6B |
| Q1 26 | $1.0B | $1.0B | ||
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.6B | $1.1B | ||
| Q2 25 | $599.0M | $1.0B | ||
| Q1 25 | $29.0M | $646.3M | ||
| Q4 24 | $1.9B | $913.0M | ||
| Q3 24 | $-93.0M | $1.0B | ||
| Q2 24 | $1.8B | $-3.6B |
| Q1 26 | — | 86.8% | ||
| Q4 25 | — | 85.4% | ||
| Q3 25 | — | 86.5% | ||
| Q2 25 | — | 86.3% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 85.5% | ||
| Q3 24 | — | 85.8% | ||
| Q2 24 | — | 85.9% |
| Q1 26 | — | 38.1% | ||
| Q4 25 | 32.3% | 37.8% | ||
| Q3 25 | 42.1% | 38.6% | ||
| Q2 25 | 19.8% | 38.8% | ||
| Q1 25 | 4.3% | 22.7% | ||
| Q4 24 | 39.5% | 35.2% | ||
| Q3 24 | 3.1% | 40.3% | ||
| Q2 24 | 39.3% | -132.9% |
| Q1 26 | 23.4% | 34.5% | ||
| Q4 25 | 28.3% | 37.3% | ||
| Q3 25 | 34.6% | 35.2% | ||
| Q2 25 | 14.4% | 34.8% | ||
| Q1 25 | 0.9% | 23.3% | ||
| Q4 24 | 35.2% | 31.4% | ||
| Q3 24 | -3.2% | 37.7% | ||
| Q2 24 | 34.2% | -135.8% |
| Q1 26 | $1.98 | $4.02 | ||
| Q4 25 | $2.58 | $4.64 | ||
| Q3 25 | $3.08 | $4.20 | ||
| Q2 25 | $1.11 | $3.99 | ||
| Q1 25 | $0.05 | $2.49 | ||
| Q4 24 | $3.45 | $3.62 | ||
| Q3 24 | $-0.17 | $4.01 | ||
| Q2 24 | $3.10 | $-13.92 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $30.0B | $19.4B |
| Total Assets | $116.3B | $26.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $5.1B | — | ||
| Q4 25 | $6.2B | $6.6B | ||
| Q3 25 | $6.8B | $6.3B | ||
| Q2 25 | $7.0B | $6.4B | ||
| Q1 25 | $5.2B | $6.2B | ||
| Q4 24 | $6.2B | $6.1B | ||
| Q3 24 | $5.6B | $6.5B | ||
| Q2 24 | $6.1B | $5.8B |
| Q1 26 | $30.0B | $19.4B | ||
| Q4 25 | $29.5B | $18.7B | ||
| Q3 25 | $28.7B | $17.3B | ||
| Q2 25 | $27.2B | $17.2B | ||
| Q1 25 | $26.3B | $16.5B | ||
| Q4 24 | $26.1B | $16.4B | ||
| Q3 24 | $24.8B | $15.6B | ||
| Q2 24 | $26.0B | $14.8B |
| Q1 26 | $116.3B | $26.5B | ||
| Q4 25 | $116.5B | $25.6B | ||
| Q3 25 | $122.3B | $24.9B | ||
| Q2 25 | $124.7B | $24.0B | ||
| Q1 25 | $120.3B | $22.9B | ||
| Q4 24 | $117.6B | $22.5B | ||
| Q3 24 | $128.4B | $22.2B | ||
| Q2 24 | $120.2B | $20.1B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AFL
Segment breakdown not available.
VRTX
| TRIKAFTA/KAFTRIO | $2.4B | 79% |
| ALYFTREK | $424.4M | 14% |
| Other | $135.9M | 5% |
| CASGEVY | $42.9M | 1% |
| Vertex recorded | $29.0M | 1% |
